Case Studies Oxford Biomedica and Antha: Multifactorial Optimisation of a Lentiviral Vector Transfection/Transduction System

Edit This Case Study Record

	Oxford Biomedica and Antha: Multifactorial Optimisation of a Lentiviral Vector Transfection/Transduction System

Oxford Biomedica and Antha: Multifactorial Optimisation of a Lentiviral Vector Transfection/Transduction System

Technology Category	Analytics & Modeling - Predictive Analytics Functional Applications - Remote Monitoring & Control Systems
Applicable Industries	Life Sciences Healthcare & Hospitals
Applicable Functions	Product Research & Development Quality Assurance
Use Cases	Predictive Quality Analytics Process Control & Optimization Remote Control
Services	Software Design & Engineering Services System Integration
Challenge	Oxford Biomedica faced the challenge of improving the efficiency and robustness of their in-house lentiviral vector production. The complexity of the biological system required a multifactorial experimental approach, which would have been very challenging to execute manually due to the number of experimental runs and the complexity of the design. Additionally, the high cost of therapy and the global demand for quality lentiviral vectors created a 'vector crunch' in the sector, necessitating the optimization of product quality, developability, and vector titres. Read More
About Customer	Oxford Biomedica is a world leader and pioneer in lentiviral vector research, manufacture, and clinical development. With over 20 years of experience in gene and cell therapy, they were the first organization to treat humans with in vivo lentiviral-based vectors. Their unique LentiVector® platform has led to a valuable portfolio of gene and cell therapy product candidates for oncological, ophthalmological, and CNS indications. In 2018, they started working with Antha to automate highly complex experiments, choosing Synthace and Antha for their rapid and flexible design and in silico simulation capabilities. Read More
Solution	Oxford Biomedica employed Antha in their R&D labs to optimize their transfection reagent mixes. Antha allowed them to save up to 40 hours on experimental planning and execution by automating the process through a liquid handling platform. The initial optimization identified transfection conditions that achieved a 3 to 10-fold increase in vector titre upon transduction, with an 81% reduction in pure error. Using Antha's DoE suite, they could rapidly define an automated liquid handling protocol, saving 95-98% of the time compared to manual methods. Antha's features also provided a 22% saving in liquid handling actions and a 32% saving in pipette tip usage. Read More Log in to view content
Contents

Technology Category

Analytics & Modeling - Predictive Analytics

Functional Applications - Remote Monitoring & Control Systems

Applicable Industries

Life Sciences

Healthcare & Hospitals

Applicable Functions

Product Research & Development

Quality Assurance

Use Cases

Predictive Quality Analytics

Process Control & Optimization

Remote Control

Services

Software Design & Engineering Services

System Integration

Challenge

Oxford Biomedica faced the challenge of improving the efficiency and robustness of their in-house lentiviral vector production. The complexity of the biological system required a multifactorial experimental approach, which would have been very challenging to execute manually due to the number of experimental runs and the complexity of the design. Additionally, the high cost of therapy and the global demand for quality lentiviral vectors created a 'vector crunch' in the sector, necessitating the optimization of product quality, developability, and vector titres.

About Customer

Oxford Biomedica is a world leader and pioneer in lentiviral vector research, manufacture, and clinical development. With over 20 years of experience in gene and cell therapy, they were the first organization to treat humans with in vivo lentiviral-based vectors. Their unique LentiVector® platform has led to a valuable portfolio of gene and cell therapy product candidates for oncological, ophthalmological, and CNS indications. In 2018, they started working with Antha to automate highly complex experiments, choosing Synthace and Antha for their rapid and flexible design and in silico simulation capabilities.

Solution

Oxford Biomedica employed Antha in their R&D labs to optimize their transfection reagent mixes. Antha allowed them to save up to 40 hours on experimental planning and execution by automating the process through a liquid handling platform. The initial optimization identified transfection conditions that achieved a 3 to 10-fold increase in vector titre upon transduction, with an 81% reduction in pure error. Using Antha's DoE suite, they could rapidly define an automated liquid handling protocol, saving 95-98% of the time compared to manual methods. Antha's features also provided a 22% saving in liquid handling actions and a 32% saving in pipette tip usage.

Impact #1	Antha allowed Oxford Biomedica to automate complex multifactorial experiments, saving significant time and resources.
Impact #2	The optimization process identified key factors and interactions, improving the robustness of the transduction process.
Impact #3	Antha's DoE suite enabled rapid and flexible definition of automated liquid handling protocols, enhancing experimental efficiency.

Impact #1

Antha allowed Oxford Biomedica to automate complex multifactorial experiments, saving significant time and resources.

Impact #2

The optimization process identified key factors and interactions, improving the robustness of the transduction process.

Impact #3

Antha's DoE suite enabled rapid and flexible definition of automated liquid handling protocols, enhancing experimental efficiency.

Benefit #1	3 to 10-fold increase in vector titre upon transduction
Benefit #2	81% reduction in pure error
Benefit #3	Up to 40 hours time saving on experimental planning and execution

Benefit #1

3 to 10-fold increase in vector titre upon transduction

Benefit #2

81% reduction in pure error

Benefit #3

Up to 40 hours time saving on experimental planning and execution

Download PDF Version

Overview

Oxford Biomedica and Antha: Multifactorial Optimisation of a Lentiviral Vector Transfection/Transduction System

Operational Impact

Quantitative Benefit